Marksans Pharma Limited

NSEI:MARKSANS 株式レポート

時価総額：₹116.0b

Marksans Pharma マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Mark Saldanha

最高経営責任者

₹63.8m

報酬総額

CEO給与比率75.28%
CEO在任期間10.7yrs
CEOの所有権43.8%
経営陣の平均在職期間11.8yrs
取締役会の平均在任期間7.2yrs

経営陣の近況

Recent updates

ナラティブの更新 • Jun 23

MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating

Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.
新しいナラティブ • Jun 15

Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile

Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?
ナラティブの更新 • Jun 04

MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating

Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
新しいナラティブ • Jun 01

Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings

Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?
分析記事 • May 29

Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...
分析記事 • May 28

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • Feb 10

Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...
分析記事 • Jan 15

Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon

It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...
分析記事 • Dec 09

Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Nov 17

Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...
ナラティブの更新 • Nov 11

MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum

Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.
分析記事 • Oct 15

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
ナラティブの更新 • Aug 15

Developed Markets Will Support Affordable Generic Expansion

Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.
分析記事 • Aug 15

Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year

NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...
分析記事 • Aug 07

Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares

NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...
分析記事 • Jun 28

Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...
分析記事 • May 27

We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings

Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...
分析記事 • May 22

₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...
分析記事 • May 14

Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
分析記事 • Mar 23

Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Mar 05

Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark

It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...
分析記事 • Feb 15

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...
分析記事 • Feb 01

Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value

Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
User avatar
新しいナラティブ • Jan 28

Teva Pharma Facility And US Expansion To Strengthen Future Outlook

Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.
分析記事 • Nov 27

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...
分析記事 • Oct 24

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
分析記事 • Sep 21

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...
分析記事 • Jul 28

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...
分析記事 • Jun 07

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...
分析記事 • May 31

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
分析記事 • Feb 16

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...
分析記事 • Jan 26

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • Dec 02

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

CEO報酬分析

Marksans Pharma の収益と比較して、Mark Saldanha の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

₹4b

Dec 31 2025n/an/a

₹4b

Sep 30 2025n/an/a

₹4b

Jun 30 2025n/an/a

₹4b

Mar 31 2025₹64m₹48m

₹4b

Dec 31 2024n/an/a

₹4b

Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹69m₹48m

₹3b

Dec 31 2023n/an/a

₹3b

Sep 30 2023n/an/a

₹3b

Jun 30 2023n/an/a

₹3b

Mar 31 2023₹52m₹48m

₹3b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹2b

Jun 30 2022n/an/a

₹2b

Mar 31 2022₹38m₹35m

₹2b

Dec 31 2021n/an/a

₹2b

Sep 30 2021n/an/a

₹2b

Jun 30 2021n/an/a

₹3b

Mar 31 2021₹10m₹10m

₹2b

Dec 31 2020n/an/a

₹2b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹10m₹10m

₹1b

報酬と市場: Markの 総報酬 ($USD 676.13K ) は、 Indian市場 ($USD 502.16K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Mark Saldanha (54 yo)

10.7yrs
在職期間
₹63,761,431
報酬

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Mark Saldanha
Non-Independent Executive Chairman & MDno data₹63.76m43.8%
₹ 50.8b
Jitendra Sharma
Group Chief Financial Officer23.8yrs₹17.99mデータなし
Harshavardhan Panigrahi
Company Secretary17.3yrs₹2.94mデータなし
Sandra Saldanha
Whole-Time Executive Non Independent Director11.8yrs₹7.07m0.073%
₹ 84.6m
Varddhman Jain
Whole-Time Executive Non Independent Director7.4yrs₹23.98mデータなし
Vishal Bhargava
Director Operationsno data₹5.80mデータなし
David Mohammed
Managing Director of Australia Operationsno dataデータなしデータなし
Sunil Rane
Senior Vice President of QCno data₹10.61mデータなし
Sathish Kumar
Managing Director of UK Operationsno dataデータなしデータなし
Anjani Kumar
Chief Operating Officer of US Operationsno data₹10.29mデータなし
Venkat Bundla
Chief Executive Officer of EU Operations1.4yrsデータなしデータなし
11.8yrs
平均在職期間
56.5yo
平均年齢

経験豊富な経営陣: MARKSANSの経営陣は経験豊富で経験豊富です（平均在職期間は11.8年）。

取締役

名称ポジション在職期間報酬所有権
Mark Saldanha
Non-Independent Executive Chairman & MD10.7yrs₹63.76m43.8%
₹ 50.8b
Sandra Saldanha
Whole-Time Executive Non Independent Director11.8yrs₹7.07m0.073%
₹ 84.6m
Varddhman Jain
Whole-Time Executive Non Independent Director7.4yrs₹23.98mデータなし
Sunny Sharma
Non-Executive & Non-Independent Director4.8yrsデータなしデータなし
Abhinna Mohanty
Non-Executive & Independent Director6.9yrs₹20.00kデータなし
Digant Parikh
Non-Executive Independent Director8.3yrs₹400.00kデータなし
Shailaja Vardhan
Non-Executive & Independent Director3.1yrs₹400.00kデータなし
Srinivas Mishra
Independent Director1.4yrsデータなしデータなし
7.2yrs
平均在職期間
55yo
平均年齢

経験豊富なボード: MARKSANSの 取締役会 は 経験豊富 であると考えられます ( 7.2年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/28 14:31
終値2026/06/25 00:00
収益2026/03/31
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Marksans Pharma Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4

アナリスト機関
Ranjit KapadiaCentrum Broking Limited
Maitri ShethChoice Equity Broking Private Limited
Nitin AgarwalDAM Capital Advisors